(Q36909124)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Allen E. Thornton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Ric M Procyshyn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Alasdair M Barr

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

7

Lili C Kopala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

4

G William MacEwan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Megan Sherwood

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Tom S Ehmann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Richard Williams

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

699-714

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17696571%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00023210-200721090-00001

3 January 2020

exact match

0 references

cites work

Content and quality of 2000 controlled trials in schizophrenia over 50 years

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Chlorpromazine in the treatment of mental illness: a study of 750 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Chlorpromazine in the treatment of neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Importance of Psychiatric Diagnosis in Prediction of Clinical Drug Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00023210-200721090-00001

Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk

21 January 2018

1 reference

12 December 2020

Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database

1 reference

12 December 2020

The NIMH-MATRICS consensus statement on negative symptoms

1 reference

12 December 2020

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

12 December 2020

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

1 reference

12 December 2020

1 reference

12 December 2020

Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach

1 reference

12 December 2020

Are the cause(s) responsible for urban-rural differences in schizophrenia risk rooted in families or in individuals?

1 reference

12 December 2020

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

1 reference

12 December 2020

Best practices: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital

1 reference

12 December 2020

The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

1 reference

12 December 2020

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model

1 reference

12 December 2020

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

12 December 2020

Effect of chlorpromazine on the behavior of chronically overactive psychotic patients.

1 reference

12 December 2020

Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry

1 reference

12 December 2020

Mediators and moderators of treatment effects in randomized clinical trials

1 reference

12 December 2020

Time course for antipsychotic treatment response in first-episode schizophrenia

1 reference

12 December 2020

Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Shared and specific susceptibility loci for schizophrenia and bipolar disorder: a dense genome scan in Eastern Quebec families

1 reference

12 December 2020

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

The genetics of adult-onset neuropsychiatric disease: complexities and conundra?

1 reference

12 December 2020

Genes for schizophrenia? Recent findings and their pathophysiological implications

1 reference

12 December 2020

The incidence of schizophrenia in European immigrants to Canada.

1 reference

12 December 2020

High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.

1 reference

12 December 2020

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

12 December 2020

Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder

1 reference

12 December 2020

Schizophrenia practice guidelines: international survey and comparison.

1 reference

12 December 2020

Differences in health values among patients, family members, and providers for outcomes in schizophrenia

1 reference

12 December 2020

Epidemiology of schizophrenia: the global burden of disease and disability

1 reference

12 December 2020

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

1 reference

12 December 2020

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

12 December 2020

Effects of family history and place and season of birth on the risk of schizophrenia

1 reference

12 December 2020

Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study

1 reference

12 December 2020

Duration of untreated psychosis and time to treatment response for delusions and hallucinations

1 reference

12 December 2020

Complexity: The bigger picture

1 reference

12 December 2020

Inpatient antipsychotic drug use in 1998, 1993, and 1989.

1 reference

12 December 2020

Schizophrenia: diverse approaches to a complex disease

1 reference

12 December 2020

Chromosome Variability and Geographic Distribution in Insects

1 reference

12 December 2020

Patterns of antipsychotic utilization in a tertiary care psychiatric institution

1 reference

12 December 2020

Current and future worldwide prevalence of dependency, its relationship to total population, and dependency ratios.

1 reference

12 December 2020

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

1 reference

12 December 2020

What does the PANSS mean?

1 reference

12 December 2020

Biomarkers and surrogate markers: an FDA perspective

1 reference

12 December 2020

Therapeutic and toxic effects of chlorpromazine among 3,-14 hospitalized cases

1 reference

12 December 2020

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

1 reference

12 December 2020

A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders

1 reference

12 December 2020

Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores

1 reference

12 December 2020

The endophenotype concept in psychiatry: etymology and strategic intentions

1 reference

12 December 2020

Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia

1 reference

12 December 2020

Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review

1 reference

12 December 2020

Experimental medicine in psychiatry

1 reference

12 December 2020

Testing for diabetes in hospitalised patients prescribed antipsychotic drugs

1 reference

12 December 2020

Combination antipsychotic therapy in clinical practice.

1 reference

12 December 2020

Evidence from biomarkers and surrogate endpoints

1 reference

12 December 2020

Long-term combination antipsychotic treatment in VA patients with schizophrenia

1 reference

12 December 2020

Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees.

1 reference

12 December 2020

Remission in schizophrenia: proposed criteria and rationale for consensus

1 reference

12 December 2020

Clinical implications of Brief Psychiatric Rating Scale scores

1 reference

12 December 2020

Clinical trial design in schizophrenia: implications for clinical decisions

1 reference

12 December 2020

Childhood head injury and expression of schizophrenia in multiply affected families

1 reference

12 December 2020

Measuring the impact of medical research: moving from outputs to outcomes

1 reference

12 December 2020

Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia.

1 reference

12 December 2020

Guideline adherence in medication management of psychotic disorders: an observational multisite hospital study.

1 reference

12 December 2020

Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients

1 reference

12 December 2020

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

12 December 2020

Multiple biomarkers for the prediction of first major cardiovascular events and death

1 reference

12 December 2020

Size of treatment effects and their importance to clinical research and practice

1 reference

12 December 2020

Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia

1 reference

12 December 2020

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

1 reference

12 December 2020

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

12 December 2020

Control group bias in randomized atypical antipsychotic medication trials for schizophrenia

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Clinicians' reasons for antipsychotic coprescribing.

1 reference

12 December 2020

Remission: what's in a name?

1 reference

12 December 2020

Multiple-informant ranking of the disabling effects of different health conditions in 14 countries. WHO/NIH Joint Project CAR Study Group

1 reference

12 December 2020

Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?

1 reference

12 December 2020

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs

1 reference

12 December 2020

Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.

1 reference

12 December 2020

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

1 reference

12 December 2020

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

1 reference

12 December 2020

A meta-analysis of profile and time-course of symptom change in acute schizophrenia treated with atypical antipsychotics.

1 reference

12 December 2020

Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice

1 reference

12 December 2020

High-cost use of second-generation antipsychotics under California's Medicaid program

1 reference

12 December 2020

Cost Analysis of the Treatment of Schizophrenia in the UK

1 reference

12 December 2020

Antipsychotic medication and cognitive function in schizophrenia.

1 reference

12 December 2020

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

12 December 2020

Schizophrenia, just the facts. What do we know, how well do we know it?

1 reference

12 December 2020

Schizophrenia: genes at last?

1 reference

12 December 2020

Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study

1 reference

12 December 2020

Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended

1 reference

12 December 2020

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

12 December 2020

The heterogeneity of schizophrenia in disease states.

1 reference

12 December 2020

Schizophrenia, neuroleptic medication and mortality

1 reference

12 December 2020

Medication augmentation after the failure of SSRIs for depression.

1 reference

12 December 2020

Variation at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis in schizophrenia and bipolar disorder.

1 reference

12 December 2020

Size of burden of schizophrenia and psychotic disorders

1 reference

12 December 2020

Cortical inhibitory neurons and schizophrenia

1 reference

12 December 2020

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

12 December 2020

Increased dopamine transmission in schizophrenia: relationship to illness phases

1 reference

12 December 2020

Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients

1 reference

12 December 2020

A comparison of outcomes among patients with schizophrenia in two mental health systems: a health state approach

1 reference

12 December 2020

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

1 reference

12 December 2020

Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia

1 reference

12 December 2020

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

1 reference

12 December 2020

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia

1 reference

12 December 2020

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

1 reference

12 December 2020

Linkage strategies for genetically complex traits. I. Multilocus models

1 reference

12 December 2020

Early prediction of antipsychotic nonresponse among patients with schizophrenia

1 reference

12 December 2020

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

1 reference

12 December 2020

Cost Analysis of the Treatment of Schizophrenia in the UK

1 reference

12 December 2020

A new grammar for drug discovery

1 reference

12 December 2020

Do urbanicity and familial liability coparticipate in causing psychosis?

1 reference

12 December 2020

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

12 December 2020

The choice of drugs for schizophrenia

1 reference

12 December 2020

Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia

1 reference

12 December 2020

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

1 reference

12 December 2020

Placebo or Active Control Trials of Antipsychotic Drugs?

1 reference

12 December 2020

Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription.

1 reference

12 December 2020

Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.

1 reference

12 December 2020

Association of Serum Antibodies to Herpes Simplex Virus 1 With Cognitive Deficits in Individuals With Schizophrenia

1 reference

12 December 2020

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.

1 reference

12 December 2020

Biomarkers: Potential Uses and Limitations

1 reference

12 December 2020

Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology

1 reference

12 December 2020

Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond

1 reference

12 December 2020

High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.

1 reference

12 December 2020

The challenge of subgroup analyses--reporting without distorting

1 reference

12 December 2020

A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.

1 reference

12 December 2020

Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected

1 reference

12 December 2020

Treatment strategies after SSRI failure--good news and bad news

1 reference

12 December 2020

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

1 reference

12 December 2020

An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand

1 reference

12 December 2020

Migration as a risk factor for schizophrenia: a Danish population-based cohort study.

1 reference

12 December 2020

Clozapine as a first treatment for schizophrenia

1 reference

12 December 2020